vs
Side-by-side financial comparison of Protagonist Therapeutics, Inc (PTGX) and Stoke Therapeutics, Inc. (STOK). Click either name above to swap in a different company.
Protagonist Therapeutics, Inc is the larger business by last-quarter revenue ($170.6M vs $158.6M, roughly 1.1× Stoke Therapeutics, Inc.). Protagonist Therapeutics, Inc runs the higher net margin — 77.2% vs 71.2%, a 6.0% gap on every dollar of revenue. On growth, Stoke Therapeutics, Inc. posted the faster year-over-year revenue change (3661.1% vs 184.4%). Protagonist Therapeutics, Inc produced more free cash flow last quarter ($182.8M vs $131.7M).
Protagonist Therapeutics, Inc. is a clinical-stage biopharmaceutical company focused on discovering and developing novel peptide-based targeted therapies for unmet medical needs, primarily covering gastrointestinal disorders, inflammatory diseases and rare disease indications. Its lead product candidates target inflammatory bowel disease and other chronic immune-related conditions, with operations spanning global R&D and partnership collaborations.
Stoke Therapeutics, Inc. is a clinical-stage biotechnology company developing innovative RNA-targeted therapies for severe rare genetic diseases. Its lead candidates address unmet needs for Dravet syndrome, a rare epilepsy, and other neurological monogenic disorders, serving patients across North America and global markets.
PTGX vs STOK — Head-to-Head
Income Statement — Q4 FY2024 vs Q1 FY2025
| Metric | | |
|---|---|---|
| Revenue | $170.6M | $158.6M |
| Net Profit | $131.7M | $112.9M |
| Gross Margin | — | — |
| Operating Margin | 74.3% | 70.2% |
| Net Margin | 77.2% | 71.2% |
| Revenue YoY | 184.4% | 3661.1% |
| Net Profit YoY | 381.7% | 528.0% |
| EPS (diluted) | $2.01 | $1.90 |
Green = leading value per metric. Periods may differ when fiscal calendars don't align.
8-Quarter Revenue & Profit Trend
Side-by-side quarterly history. Quarters aligned by calendar period so offset fiscal years line up.
| Q1 25 | — | $158.6M | ||
| Q4 24 | $170.6M | $22.6M | ||
| Q1 24 | $255.0M | — | ||
| Q3 23 | $0 | — | ||
| Q2 23 | $0 | $-2.5M | ||
| Q1 23 | $0 | — | ||
| Q4 22 | $0 | — | ||
| Q3 22 | $0 | — |
| Q1 25 | — | $112.9M | ||
| Q4 24 | $131.7M | $-10.5M | ||
| Q1 24 | $207.3M | — | ||
| Q3 23 | $-34.1M | — | ||
| Q2 23 | $-38.5M | $-30.7M | ||
| Q1 23 | $-33.7M | — | ||
| Q4 22 | — | — | ||
| Q3 22 | $-31.2M | — |
| Q1 25 | — | 70.2% | ||
| Q4 24 | 74.3% | -60.4% | ||
| Q1 24 | 80.9% | — | ||
| Q3 23 | — | — | ||
| Q2 23 | — | 1340.7% | ||
| Q1 23 | — | — | ||
| Q4 22 | — | — | ||
| Q3 22 | — | — |
| Q1 25 | — | 71.2% | ||
| Q4 24 | 77.2% | -46.4% | ||
| Q1 24 | 81.3% | — | ||
| Q3 23 | — | — | ||
| Q2 23 | — | 1235.6% | ||
| Q1 23 | — | — | ||
| Q4 22 | — | — | ||
| Q3 22 | — | — |
| Q1 25 | — | $1.90 | ||
| Q4 24 | $2.01 | $-0.15 | ||
| Q1 24 | $3.26 | — | ||
| Q3 23 | $-0.58 | — | ||
| Q2 23 | $-0.68 | $-0.69 | ||
| Q1 23 | $-0.67 | — | ||
| Q4 22 | — | — | ||
| Q3 22 | $-0.64 | — |
Balance Sheet & Financial Strength
Snapshot of each company's liquidity, leverage and book value from the latest quarter.
| Metric | | |
|---|---|---|
| Cash + ST InvestmentsLiquidity on hand | $418.9M | $274.8M |
| Total DebtLower is stronger | — | — |
| Stockholders' EquityBook value | $675.3M | $350.1M |
| Total Assets | $744.7M | $406.9M |
| Debt / EquityLower = less leverage | — | — |
8-quarter trend — quarters aligned by calendar period.
| Q1 25 | — | $274.8M | ||
| Q4 24 | $418.9M | $128.0M | ||
| Q1 24 | $322.6M | — | ||
| Q3 23 | $320.8M | — | ||
| Q2 23 | $313.4M | $192.1M | ||
| Q1 23 | $230.8M | — | ||
| Q4 22 | $237.4M | — | ||
| Q3 22 | $267.4M | — |
| Q1 25 | — | $350.1M | ||
| Q4 24 | $675.3M | $229.0M | ||
| Q1 24 | $560.4M | — | ||
| Q3 23 | $302.1M | — | ||
| Q2 23 | $294.1M | $190.2M | ||
| Q1 23 | $216.2M | — | ||
| Q4 22 | $215.6M | — | ||
| Q3 22 | $243.6M | — |
| Q1 25 | — | $406.9M | ||
| Q4 24 | $744.7M | $271.6M | ||
| Q1 24 | $629.3M | — | ||
| Q3 23 | $330.0M | — | ||
| Q2 23 | $320.5M | $256.9M | ||
| Q1 23 | $239.9M | — | ||
| Q4 22 | $247.9M | — | ||
| Q3 22 | $282.2M | — |
Cash Flow & Capital Efficiency
How much cash each business actually produces after reinvestment. Cash flow is harder to manipulate than net income.
| Metric | | |
|---|---|---|
| Operating Cash FlowLast quarter | $184.2M | $131.8M |
| Free Cash FlowOCF − Capex | $182.8M | $131.7M |
| FCF MarginFCF / Revenue | 107.1% | 83.0% |
| Capex IntensityCapex / Revenue | 0.8% | 0.1% |
| Cash ConversionOCF / Net Profit | 1.40× | 1.17× |
| TTM Free Cash FlowTrailing 4 quarters | $101.7M | — |
8-quarter trend — quarters aligned by calendar period.
| Q1 25 | — | $131.8M | ||
| Q4 24 | $184.2M | $-23.2M | ||
| Q1 24 | $-27.4M | — | ||
| Q3 23 | $-26.6M | — | ||
| Q2 23 | $-26.2M | $-21.8M | ||
| Q1 23 | $-34.3M | — | ||
| Q4 22 | $-108.1M | — | ||
| Q3 22 | $-25.2M | — |
| Q1 25 | — | $131.7M | ||
| Q4 24 | $182.8M | $-23.2M | ||
| Q1 24 | $-27.7M | — | ||
| Q3 23 | $-27.0M | — | ||
| Q2 23 | $-26.4M | $-22.6M | ||
| Q1 23 | $-34.4M | — | ||
| Q4 22 | $-108.9M | — | ||
| Q3 22 | $-25.4M | — |
| Q1 25 | — | 83.0% | ||
| Q4 24 | 107.1% | -102.7% | ||
| Q1 24 | -10.9% | — | ||
| Q3 23 | — | — | ||
| Q2 23 | — | 912.5% | ||
| Q1 23 | — | — | ||
| Q4 22 | — | — | ||
| Q3 22 | — | — |
| Q1 25 | — | 0.1% | ||
| Q4 24 | 0.8% | 0.2% | ||
| Q1 24 | 0.1% | — | ||
| Q3 23 | — | — | ||
| Q2 23 | — | -33.8% | ||
| Q1 23 | — | — | ||
| Q4 22 | — | — | ||
| Q3 22 | — | — |
| Q1 25 | — | 1.17× | ||
| Q4 24 | 1.40× | — | ||
| Q1 24 | -0.13× | — | ||
| Q3 23 | — | — | ||
| Q2 23 | — | — | ||
| Q1 23 | — | — | ||
| Q4 22 | — | — | ||
| Q3 22 | — | — |
Financial Flow Comparison
Revenue → gross profit → operating profit → net profit for each company.
